Bronchogen — EU research guide.
Bronchogen is a synthetic tetrapeptide (Ala-Glu-Asp-Leu) from the Khavinson short peptide bioregulator series — the same research family as Epitalon, Vilon, Thymalin, Cortagen and Crystagen, which PeptideCompare already tracks. It is proposed to act on bronchopulmonary tissue, theoretically by influencing gene expression patterns specific to lung epithelial cells.
What is Bronchogen?
Bronchogen is a synthetic tetrapeptide (Ala-Glu-Asp-Leu) from the Khavinson short peptide bioregulator series — the same research family as Epitalon, Vilon, Thymalin, Cortagen and Crystagen, which PeptideCompare already tracks. It is proposed to act on bronchopulmonary tissue, theoretically by influencing gene expression patterns specific to lung epithelial cells.
What does the research show?
Published research comes almost entirely from Russian and Eastern European laboratories associated with the original Khavinson research group, reporting reduced markers of pulmonary inflammation and improved respiratory tissue parameters in animal models and small observational human cohorts. No large-scale, independently replicated randomized controlled trials have been published in mainstream Western journals as of mid-2026.
EU legal status
Not approved as a medicine anywhere in the EU. A small number of specialist research vendors sell it as a peptide bioregulator for laboratory research only.
Molecular information
Pharmacokinetics
Bronchogen is not yet in our price comparison
We expand EU supplier coverage every month.